Beautiful Virgin Islands

Saturday, Jul 26, 2025

Hong Kong looking to procure world’s first Covid-19 pill

Hong Kong looking to procure world’s first Covid-19 pill

Sources tell the Post that Hospital Authority is planning to buy hundreds of courses of the antiviral medication, known as molnupiravir.

Hong Kong is in the process of securing the world’s first Covid-19 pill, which the manufacturers claim can cut hospitalisations and deaths by half.

Sources told the Post that health authorities planned to buy hundreds of courses of the antiviral medication, which made headlines on Friday after pharmaceutical giant MSD and its partner Ridgeback Biotherapeutics released promising results from their trials.

The trials involved 775 adults with mild to moderate Covid-19 who were randomly picked from more than 20 countries and deemed to be highly prone to severe illness due to health problems such as obesity, diabetes or heart disease.

Half of the trial participants were given a five-day course of the experimental drug, known as molnupiravir, in the form of small, brown capsules taken twice a day, while the others received a placebo. According to the results, only 28 patients, or 7.3 per cent, of those given the drug were hospitalised, compared with 53, or 14.1 per cent, in the placebo group.

After the trial, no deaths were reported among those who received the drug, while the placebo group had eight. The data, however, has not been peer-reviewed and the drug has not yet been licensed for use.

Three medical sources confirmed to the Post that Hong Kong was looking to procure the medication.

“The Hospital Authority plans to purchase 500 patient courses, but they are also thinking about more,” Professor David Hui Shu-cheong, a government pandemic adviser, said on Saturday.

Professor David Hui.


He revealed that the drug costs about US$700 per course for each patient.

Hui and other authority doctors said they hoped the matter would be discussed at the next meeting of the Centre for Health Protection’s joint scientific committees, which was likely to take place in late October or early November.

Another source familiar with the matter said negotiations between MSD, which trades as Merck in North America, and the authority were continuing and that “no paperwork has been signed” yet.

A third source said the drug could be approved for emergency use to treat severely ill patients although it was not yet licensed by local health authorities.

“It would, however, be difficult to conduct any local study on its effectiveness, as we fortunately have so few patients in the community, and most imported cases have a low viral load,” the health expert said.

Infectious disease expert Professor Ivan Hung Fan-ngai, who has looked at the trial data, said molnupiravir achieved the best results with a daily dosage of 800 milligrams given in the first week of illness, rather than lower amounts of 400 or 200 milligrams.

“It works best when given early and results in fewer hospitalisations and deaths subsequently,” he said.

Merck, which trades as MSD outside North America, released trial data on Friday.


Hung, who co-chairs a government panel on adverse vaccine effects, noted the city’s cocktail therapy for Covid-19 centred on the antiviral interferon, which also achieved its best results when given early.

“In general, early treatment is the key to success for all antivirals,” he said.

A Hospital Authority source said it had been monitoring the drug’s development.

“It has been on our radar all along, but we can’t say how the company will distribute the drug globally,” the source said, noting that US authorities had yet to authorise the pill for emergency use.

An authority spokesman said its experts had been closely monitoring the latest developments in the pandemic and clinical research. It would buy and stock medications for Covid-19 when necessary, after taking reference from the latest data from worldwide drug regulatory agencies and manufacturers.

The authority would ensure patients were prescribed new medications that were proven safe and effective, the spokesman said.

The Department of Health said it had not received any application for the registration of molnupiravir. Under the Pharmacy and Poisons Ordinance, doctors can import drugs that are not yet registered in the city for treating specific patients or conducting clinical trials.

MSD said it would apply for approval for emergency use for the drug in the United States within the next two weeks and make applications in several other countries as well.

The Post has contacted the drugmaker for comment.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Deputy attorney general's second day of meeting with Ghislaine Maxwell has concluded
Controversial March in Switzerland Features Men Dressed in Nazi Uniforms
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
Thai Civilian Death Toll Rises to 12 in Cambodian Cross-Border Attacks
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
×